
OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Tax Provision
OSE Immunotherapeutics SA
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
OSE Immunotherapeutics SA
PAR:OSE
|
Tax Provision
-€3.4m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
![]() |
Valneva SE
PAR:VLA
|
Tax Provision
-€761k
|
CAGR 3-Years
40%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-9%
|
|
![]() |
Nanobiotix SA
PAR:NANO
|
Tax Provision
-€261k
|
CAGR 3-Years
-197%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
G
|
Genfit SA
PAR:GNFT
|
Tax Provision
-€5k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Inventiva SA
PAR:IVA
|
Tax Provision
-€733k
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
Tax Provision
-€3.3m
|
CAGR 3-Years
47%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

See Also
What is OSE Immunotherapeutics SA's Tax Provision?
Tax Provision
-3.4m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Tax Provision amounts to -3.4m EUR.
What is OSE Immunotherapeutics SA's Tax Provision growth rate?
Tax Provision CAGR 5Y
-18%
The average annual Tax Provision growth rates for OSE Immunotherapeutics SA have been -44% over the past three years , -18% over the past five years .